Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jun 14:9:866518.
doi: 10.3389/fnut.2022.866518. eCollection 2022.

Use of Teduglutide in Children With Intestinal Failure: A Systematic Review

Francesca Gigola  1 , Maria Chiara Cianci  1 , Roberto Cirocchi  2 , Maria Chiara Ranucci  3 , Marco Del Riccio  4 , Riccardo Coletta  1   5 , Antonino Morabito  1   6
Affiliations

Use of Teduglutide in Children With Intestinal Failure: A Systematic Review

Francesca Gigola et al. Front Nutr. .

Abstract

Background and objectives: Short-bowel syndrome (SBS) results from the loss of a significant portion of the small intestine leading to a state of malabsorption. After an intestinal loss, there is a process of adaptation involving the Glucagon-Like Peptide-2 (GLP-2), an enteroendocrine peptide also involved in nutrient absorption. Teduglutide is a recombinant analog of GLP-2 approved in 2016 to treat selected SBS pediatric patients who are dependent on parenteral support. The present systematic review aims to evaluate the efficacy of Teduglutide in pediatric patients with SBS in reducing the need for parenteral nutrition (PN).

Materials and methods: We performed a literature search on MEDLINE and Embase to include articles up to November 2021. We included articles that involved using Teduglutide in the SBS pediatric population to define its efficacy in reducing the need for PN. The key words used were GLP-2, teduglutide, child.

Results: Fourteen studies completely fulfilled the inclusion criteria. Two hundred 23 patients were treated with Teduglutide, and the median duration of treatment was 45 weeks (IQR: 36-52.5 weeks). One-hundred and fifty-two patients were treated with 0.05 mg/Kg/d of subcutaneous Teduglutide, 38 received 0.025 mg/Kg/d and 8 received either 0.125 mg/Kg/d or 0.20 mg/Kg/d. A total of 36 patients achieved enteral autonomy (EA) after a median of 24 weeks of treatment (IQR: 24-48 weeks) and 149 patients showed a reduction in PN needs in terms of volume, calories, or hours per day. Eleven studies reported complications: gastrointestinal were the most common, with 89 cases reported in treated patients and 11 in non-treated patients.

Conclusion: Teduglutide appears safe and effective in reducing PN requirements and improving EA in the pediatric population. However, more studies are needed to understand its efficacy in the long term and after discontinuation and possible complications.

Systematic review registration: [https://www.crd.york.ac.uk/prospero/], identifier [CRD42022301593].

Keywords: glucagon-like peptide 2; intestinal adaptation; malabsorption; parenteral nutrition; rare disease; short bowel syndrome.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
PRISMA flowchart.
FIGURE 2
FIGURE 2
Quality assessment results according to ROBINS-I.
See this image and copyright information in PMC

References

    1. Nagelkerke SCJ, van Oers HA, Haverman L, Vlug LE, de Koning BAE, Benninga MA, et al. Longitudinal development of health-related quality of life and fatigue in children on home parenteral nutrition. J Pediatr Gastroenterol Nutr. (2022) 74:116–22. 10.1097/MPG.0000000000003329 - DOI - PMC - PubMed
    1. Muto M, Kaji T, Onishi S, Yano K, Yamada W, Ieiri S. An overview of the current management of short-bowel syndrome in pediatric patients. Surg Today. (2022) 52:12–21. 10.1007/s00595-020-02207-z - DOI - PubMed
    1. Struijs M-C, Diamond IR, de Silva N, Wales PW. Establishing norms for intestinal length in children. J Pediatr Surg. (2009) 44:933–8. 10.1016/j.jpedsurg.2009.01.031 - DOI - PubMed
    1. Coletta R, Aldeiri B, Morabito A. Institutional experience with spiral intestinal lengthening and tailoring. Eur J Pediatr Surg. (2018) 29:412–6. 10.1055/s-0038-1660850 - DOI - PubMed
    1. Quirós-Tejeira RE, Ament ME, Reyen L, Herzog F, Merjanian M, Olivares-Serrano N, et al. Long-term parenteral nutritional support and intestinal adaptation in children with short bowel syndrome: a 25-year experience. J Pediatr. (2004) 145:157–63. 10.1016/j.jpeds.2004.02.030 - DOI - PubMed

Publication types

LinkOut - more resources